Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar;8(1):34-9.
doi: 10.1007/s11914-010-0007-2.

Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates

Affiliations
Review

Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates

Jeri W Nieves et al. Curr Osteoporos Rep. 2010 Mar.

Abstract

Several case series and multiple individual case reports suggest that some subtrochanteric and femoral shaft fractures might occur in patients who have been treated with long-term bisphosphonates. Several unique clinical and radiographic features are emerging: prodromal thigh pain prior to the fracture, complete absence of trauma precipitating the fracture, and bilateral fractures in some patients. Radiographic features include presence of stress reaction, transverse or short oblique fractures, and thick femoral cortices. The overall incidence of subtrochanteric and shaft fractures combined is below 30 per 100,000 person-years, so this type of fracture is much less common than proximal femur (hip) fracture. Furthermore, the unique "atypical" fracture type is a subset of all subtrochanteric and femoral shaft fractures. The putative mechanism is unknown, and more research is needed to identify distinctive characteristics and the pathophysiology of these atypical fractures. There is no rationale to withhold bisphosphonate therapy from patients with osteoporosis, although continued use of bisphosphonate therapy beyond a treatment period of 3 to 5 years should be re-evaluated annually.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Endocrinol (Oxf). 2010 Feb;72(2):161-8 - PubMed
    1. Geriatrics. 2006 Jan;61(1):31-3 - PubMed
    1. J Clin Endocrinol Metab. 2008 Aug;93(8):2948-52 - PubMed
    1. J Bone Miner Res. 2009 Oct;24(10):1736-40 - PubMed
    1. Endocr Pract. 2009 Jul-Aug;15(5):483-93 - PubMed

MeSH terms

Substances

LinkOut - more resources